Keytruda for mesothelioma – pro
Recent AACR metting presented an early study of 25 mesothelioma patients who had tumors with the PD-L1 protein, for which chemotherapy proved unsuccessful, 76 percent saw improvements after an average of 5½ months of treatment. Tumors shrank in 28 percent of patients while tumors stopped growing completely in another 48 percent. Compared to chemotherapy, the side effects of Keytruda were also more tolerable. The ongoing study is Pembrolizumab in Treating Patients With Malignant Mesothelioma, NCT02399371.
NCCN, Malignant Pleural Mesotherlioma, MPM-A 2017
KEYNOTE-028, http://www.mercknewsroom.com/news-release/oncology-newsroom/early-findings-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-patien